EE359 Real-World Utilization, Treatment Frequency, and Bleeding Outcomes on Damoctocog Alfa Pegol in Haemophilia A Care: Insights From a German Cohort Within the CHESS II Study
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.605
https://www.valueinhealthjournal.com/article/S1098-3015(22)02809-1/fulltext
Title :
EE359 Real-World Utilization, Treatment Frequency, and Bleeding Outcomes on Damoctocog Alfa Pegol in Haemophilia A Care: Insights From a German Cohort Within the CHESS II Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02809-1&doi=10.1016/j.jval.2022.09.605
First page :
Section Title :
Open access? :
No
Section Order :
10136